<DOC>
	<DOC>NCT02294344</DOC>
	<brief_summary>The clinical efficacy of double filtration plasmapheresis(DFPP) in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).</brief_summary>
	<brief_title>The Clinical Efficacy of DFPP in Patients With AAGN</brief_title>
	<detailed_description>This is a single center, prospective, randomized,controlled study to compare the clinical efficacy of double filtration plasmapheresis (DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy versus IV-CTX pulse therapy in patients with antineutrophil cytoplasmic autoantibody associated glomerulonephritis(AAGN).</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference serum positive ANCA and the ANCA level ≥100 relative unit/ml with renal involvement and serum creatinine≥3 mg/dl written informed consent had been provided. other secondary vasculitis antiglomerular basement membrane(GBM) positive severe infection; hepatitis B antigenemia, anti hepatitis C virus immunodeficiency; or immunoglobulin G(IgG)&lt;2g/l life threatening renal biopsy show globally sclerotic glomeruli&gt;60% and normal glomeruli&lt;10% need renal replacement therapy for more than 4w received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>double filtration plasmapheresis</keyword>
	<keyword>ANCA-Associated Vasculitis</keyword>
</DOC>